CpG and transfer factor assembled on nanoparticles reduce tumor burden in mice glioma model

Miao, Yi; Lv, Tao; Wang, Ran; Wu, Hui; Yang, Shaofeng; Dai, Jiong; Zhang, Xiaohua

doi:10.1039/c6ra17395k

Cited by 3 publications

(2 citation statements)

References 36 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…The production of cytokines from macrophages or DCs was evaluated using ELISA kits by following the manufacturer's instructions. We followed the methods of Miao et al [ 32 ].…”

Section: Methodsmentioning

confidence: 99%

The Biocomplex Assembled from Antigen Peptide and Toll-like Receptor Agonist Improved the Immunity against Pancreatic Adenocarcinoma In Vivo

Feng

Xue

et al. 2022

Journal of Oncology

View full text Add to dashboard Cite

Purpose. One of the biggest challenges in cancer immunotherapy is generating robust cancer-specific immunity. This work describes using a biocomplex assembled from a toll-like receptor agonist CpG oligodeoxynucleotide 1826 (CpG) and a pancreatic cancer antigen peptide mesothelin for tuning pancreatic tumor immunity. Methods. This biocomplex was assembled via electrostatic interactions and characterized in size, morphology, zeta potential, and cargo loading. The effect of biocomplex on cell viability and activation of DCs and macrophages were measured by flow cytometry. The production of cytokines (GM-CSF, TNF, and IL-6) was evaluated by using ELISA kits. The effect of biocomplex on tumor cell proliferation was also evaluated by in vivo tumor model. Result. We can modulate the surface charge of the biocomplex by simply varying the ratios of the two components. In cell models, this biocomplex did not impact cell viability in the antigen-presenting cell (i.e., dendritic cell and macrophage)-directed immunity. Moreover, this biocomplex regulated the secretion of tumor-related cytokines (i.e., GM-CSF, TNF, and IL-6) and promoted the activation of immune cell surface markers (i.e., CD80+, CD86+, and CD40+). In the mouse model, the biocomplex inhibited the tumor burden effectively and promoted the production of effector cytokines. Conclusion. The present studies showed that the biocomplex with antigen peptide and toll-like receptor agonist was able to potentiate the antitumor immunity in vivo. This study will help understanding of immunity in pancreatic cancer and developing new immune therapeutic strategies for pancreatic adenocarcinoma.

show abstract

“…The production of cytokines from macrophages or DCs was evaluated using ELISA kits by following the manufacturer's instructions. We followed the methods of Miao et al [ 32 ].…”

Section: Methodsmentioning

confidence: 99%

The Biocomplex Assembled from Antigen Peptide and Toll-like Receptor Agonist Improved the Immunity against Pancreatic Adenocarcinoma In Vivo

Feng

Xue

et al. 2022

Journal of Oncology

View full text Add to dashboard Cite

show abstract

“…After the CDDP enters the body, the chlorine atoms are gradually replaced by water molecules to form [Pt(H 2 O) 2 (NH 3 ) 2 ] + 128. Platinum crosslinks with two bases on the DNA to form a closed chain or inter-chain adduct, which inhibits the DNA replication process of cancer cells, leading to apoptosis 129-132. At the cellular level, CDDP could impact various cellular components through nucleophilic sites, then results in cell malfunction and death 124.…”

Section: Chemotherapy and Molecular Targeted Therapy Of Hepatoma Withmentioning

confidence: 99%

Evaluation of Polymer Nanoformulations in Hepatoma Therapy by Established Rodent Models

Wang

Zhang

et al. 2019

Theranostics

View full text Add to dashboard Cite

Hepatoma is one of the most severe malignancies usually with poor prognosis, and many patients are insensitive to the existing therapeutic agents, including the drugs for chemotherapy and molecular targeted therapy. Currently, researchers are committed to developing the advanced formulations with controlled drug delivery to improve the efficacy of hepatoma therapy. Numerous inoculated, induced, and genetically engineered hepatoma rodent models are now available for formulation screening. However, animal models of hepatoma cannot accurately represent human hepatoma in terms of histological characteristics, metastatic pathways, and post-treatment responses. Therefore, advanced animal hepatoma models with comparable pathogenesis and pathological features are in urgent need in the further studies. Moreover, the development of nanomedicines has renewed hope for chemotherapy and molecular targeted therapy of advanced hepatoma. As one kind of advanced formulations, the polymer-based nanoformulated drugs have many advantages over the traditional ones, such as improved tumor selectivity and treatment efficacy, and reduced systemic side effects. In this article, the construction of rodent hepatoma model and much information about the current development of polymer nanomedicines were reviewed in order to provide a basis for the development of advanced formulations with clinical therapeutic potential for hepatoma.

show abstract

Gold nanoparticles as an adjuvant: Influence of size, shape, and technique of combination with CpG on antibody production

Дыкман¹,

Староверов

Фомин

et al. 2018

International Immunopharmacology

View full text Add to dashboard Cite

CpG and transfer factor assembled on nanoparticles reduce tumor burden in mice glioma model

Abstract: This work describes the use of a transfer factor, a low molecular protein that can transfer cell mediated immunity from donor to recipient, and CpG, a clinically relevant toll-like receptor agonist, for treating glioma.

Cited by 3 publications

References 36 publications

The Biocomplex Assembled from Antigen Peptide and Toll-like Receptor Agonist Improved the Immunity against Pancreatic Adenocarcinoma In Vivo

The Biocomplex Assembled from Antigen Peptide and Toll-like Receptor Agonist Improved the Immunity against Pancreatic Adenocarcinoma In Vivo

Evaluation of Polymer Nanoformulations in Hepatoma Therapy by Established Rodent Models

Gold nanoparticles as an adjuvant: Influence of size, shape, and technique of combination with CpG on antibody production

Contact Info

Product

Resources

About